104 related articles for article (PubMed ID: 16762510)
1. Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review.
Berardi R; Scartozzi M; Freddari F; Squadroni M; Santinelli A; Bearzi I; Fabris G; Cascinu S
Cancer Treat Rev; 2006 Aug; 32(5):333-47. PubMed ID: 16762510
[TBL] [Abstract][Full Text] [Related]
2. Emerging treatment with systemic chemotherapy and targeted agents for biliary cancers.
Boku N
Curr Opin Investig Drugs; 2010 Jun; 11(6):653-60. PubMed ID: 20496260
[TBL] [Abstract][Full Text] [Related]
3. Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy.
Thomas MB
Crit Rev Oncol Hematol; 2007 Jan; 61(1):44-51. PubMed ID: 17164111
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy in biliary tract cancer.
Tonini G; Frato ME; Vincenzi B; Santini D
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):371-4. PubMed ID: 20496551
[TBL] [Abstract][Full Text] [Related]
5. Toward personalized treatment of advanced biliary tract cancers.
Geynisman DM; Catenacci DV
Discov Med; 2012 Jul; 14(74):41-57. PubMed ID: 22846202
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer.
Coley HM
Cancer Treat Rev; 2008 Jun; 34(4):378-90. PubMed ID: 18367336
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers.
Capdevila J; Ramos FJ; Macarulla T; Elez E; Ruiz-Echarri M; Perez-Garcia J; Tabernero J
Curr Opin Oncol; 2009 Jul; 21(4):374-80. PubMed ID: 19412097
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy in biliary tract cancer: 2009 update.
Tonini G; Virzì V; Fratto ME; Vincenzi B; Santini D
Future Oncol; 2009 Dec; 5(10):1675-84. PubMed ID: 20001803
[TBL] [Abstract][Full Text] [Related]
11. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.
El Maalouf G; Le Tourneau C; Batty GN; Faivre S; Raymond E
Cancer Treat Rev; 2009 Apr; 35(2):167-74. PubMed ID: 19027240
[TBL] [Abstract][Full Text] [Related]
12. S-1 monotherapy in patients with advanced biliary tract cancer.
Sasaki T; Isayama H; Yashima Y; Yagioka H; Kogure H; Arizumi T; Togawa O; Matsubara S; Ito Y; Nakai Y; Sasahira N; Hirano K; Tsujino T; Tada M; Kawabe T; Omata M
Oncology; 2009; 77(1):71-4. PubMed ID: 19556812
[TBL] [Abstract][Full Text] [Related]
13. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticles for delivery of chemotherapeutic agents to tumors.
Vijayaraghavalu S; Raghavan D; Labhasetwar V
Curr Opin Investig Drugs; 2007 Jun; 8(6):477-84. PubMed ID: 17621878
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Miller WR; Larionov A; Renshaw L; Anderson TJ; Walker JR; Krause A; Sing T; Evans DB; Dixon JM
J Clin Oncol; 2009 Mar; 27(9):1382-7. PubMed ID: 19224856
[TBL] [Abstract][Full Text] [Related]
17. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Furuse J; Okusaka T; Funakoshi A; Yamao K; Nagase M; Ishii H; Nakachi K; Ueno H; Ikeda M; Morizane C; Horikawa Y; Mizuno N
Jpn J Clin Oncol; 2006 Sep; 36(9):552-6. PubMed ID: 16887837
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer.
Stockmans G; Deraedt K; Wildiers H; Moerman P; Paridaens R
Curr Opin Oncol; 2008 Nov; 20(6):614-20. PubMed ID: 18841042
[TBL] [Abstract][Full Text] [Related]
19. Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase II study.
Cantore M; Fiorentini G; Mambrini A; Rabbi C; Zamagni D; Carlone N; Manni A; Caudana R; Torri T
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):59-64. PubMed ID: 16767908
[TBL] [Abstract][Full Text] [Related]
20. Novel targets and approaches in advanced prostate cancer.
Hadaschik BA; Sowery RD; Gleave ME
Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
